Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02818920 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Pembrolizumab
A Phase 2 study of Non-Small-Cell Lung Carcinoma, sponsored by Neal Ready MD PhD.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 3
- Study locations
NCT02818920 is a Phase 2 study of Non-Small-Cell Lung Carcinoma that has completed, run by Neal Ready MD PhD. The registered enrollment target is 35 participants, below the 235-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT02818920, a Phase 2 study of Non-Small-Cell Lung Carcinoma, has completed, sponsored by Neal Ready MD PhD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 3
- Study locations
Study Summary
This multi-institutional, phase 2 clinical trial is studying two doses of pembrolizumab administered prior to surgery (neoadjuvant therapy) and 4 doses administered after surgery (adjuvant therapy) for stage IB, II or IIIA non-small cell lung cancer. Pembrolizumab is a type of immunotherapy that may enhance the ability of the immune system to fight off cancer. The study will investigate the effects of pembrolizumab on the immune system and how certain immune cells, called TILs (tumor infiltrating lymphocytes), respond to pembrolizumab. Previous studies suggest that pembrolizumab could alter the immune cells in a way that the the immune cells identify cancer cells. Pembrolizumab has been approved for the treatment of advanced lung cancer, but is investigational in this setting.
Conditions Studied
Interventions
- DRUG Pembrolizumab
Study Locations (3)
Minnesota
- Mayo Clinic - Rochester
New Hampshire
- Dartmouth-Hitchcock Medical Center - Lebanon
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2017-01 |
| Est. Completion | 2024-06-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02818920
The ClinicalTrials.gov registry entry for NCT02818920 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 235-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target (85% lower). The listed sponsor is Neal Ready MD PhD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small-Cell Lung Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT02818920 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Minnesota, New Hampshire, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02818920 about?
NCT02818920 is a clinical study titled "Neoadjuvant Pembrolizumab". This multi-institutional, phase 2 clinical trial is studying two doses of pembrolizumab administered prior to surgery (neoadjuvant therapy) and 4 doses administered after surgery (adjuvant therapy) for stage IB, II or IIIA non-small cell lung cancer. Pembrolizumab is a type of immunotherapy that may...
What is the current status of trial NCT02818920?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2017-01. Estimated completion is 2024-06-20.
What conditions does trial NCT02818920 study?
This clinical trial studies the following conditions: Non-Small-Cell Lung Carcinoma.
What interventions are being tested in trial NCT02818920?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT02818920?
This trial is sponsored by Neal Ready MD PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02818920 being conducted?
This trial has 3 study locations across Minnesota, New Hampshire, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small-Cell Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC
ACTIVE NOT RECRUITING · Phase 2
-
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
ACTIVE NOT RECRUITING · Phase 2
-
Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients
COMPLETED · Phase 2
-
Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence
COMPLETED · Phase 2
-
Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.
COMPLETED · Phase 2
-
Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.